Medytox signs botulinum toxin distribution agreement worth USD 73 million with Blau Farmacêutica, from Brazil - Blau Farmacêutica S.A. (Brazil B3 BLAU3) will distribute Medytox’s products in the Brazilian market on an exclusive basis…concluding its prior contract with Hugel by the end of this year - Medytox sets foundation for large-scale exports of botulinum toxin products with minimum order quantity totaling USD 73 million…accelerating penetration in the Latin America (LATAM) market, starting from Brazil. - Hee-Seok Ju, Executive Vice President of Medytox, states, “The partnership with Blau affirms Medytox’s botulinum toxin technology”…“we will create the best synergy with Blau, the perfect partner for Medytox targeting the LATAM market” Medytox (CEO Hyun Ho Jung) announced on March 26th, 2024 that the biopharmaceutical company had entered into a distribution agreement (the “Agreement”) with BLAU FARMACEUTICA S.A. (CEO Marcelo Hahn) for botulinum toxin at USD 73 million (based on minimum order quantity) for five years. Medytox will supply its botulinum toxin products (including Newlux) to Blau, which will distribute Medytox’s products in the territory of Brazil. The long-term Agreement came in the aftermath of Blau’s acquisition in Brazil of Laboratorio Químico e Farmacêutico Bergamo LTDA, the previous partner of Medytox. On the occasion of its new partnership with Medytox, Blau has decided to conclude its prior contract with Hugel and transfer it to a 3rd party along 2024.Medytox launched Meditoxin (Export Name: Botulift) in Brazil in 2010, the first botulinum toxin developed in South Korea, and has since expanded its exports, recording over USD 16 million-worth exports to Brazil in 2023 only. Such result is equivalent to 30% of Medytox overseas botulinum toxin revenue (USD 46.5 million in 2023).Hee-Seok Ju, Executive Vice President of Medytox, states, “As Blau has deep trust in Medytox’s advanced R&D capabilities and specialties achieved by its 20-year focus on botulinum toxin, we have reached this agreement with great pleasure” and “we will create the best synergy with Blau, the perfect partner for Medytox targeting the LATAM market”Roberto Morais, Executive Director of Strategy and M&A, states, “we are very happy with this partnership, Medytox has a long experience on aesthetics products, including botulinum toxin, and very strong R&D capabilities with a solid pipeline, that can offer us new products in the future to be distributed in the region, boosting Blau´s Aesthetics Business Unit.”On the other hand, based on the Agreement, Medytox will accelerate penetration in the Brazilian market with Newlux (product developed by Numeco – 100% subsidiary of Medytox). Numeco is currently expanding the domestic market share of Newlux, a product approved by the KFDA (August 2023), as well as trying to obtain the approval for ROW countries.About Medytox Group: Medytox is a research-based bio pharmaceutical company that developed a botulinum toxin product for the first time in South Korea (the fourth in the world), and engages in the development, manufacture, marketing and sales of neurotoxin products as its main business. Since its establishment in 2000, Medytox has developed and evolved into a global world-class R&D company with the successful launch of its main neurotoxin product. Medytox Group is the only bio pharmaceutical company who possess 4 types of botulinum toxin – Neuronox® (900kDa botulinum toxin in powder type / approved worldwide), Innotox® (900kDa botulinum toxin in liquid type / approved in South Korea only), Coretox® (150kDa botulinum toxin in powder type approved in South Korea only) and Newlux® (900kDa botulinum toxin in powder type / approved in South Korea only).About Blau Farmacêutica: Blau is a leading pharmaceutical company in the institutional segment and a pioneer in biotechnology, with a portfolio of owned brands of highly complex drugs focused on relevant segments in the industry, such as immunology, hematology, oncology, nephrology, and infectious diseases, among others, acting in several therapeutical classes. Blau is present across the continent, currently in eight countries in Latin America (Brazil, Argentina, Colombia, Chile, Equator, Peru, Uruguay and Mexico), in the United States, and in Europe, with a modern pharmaceutical industrial complex composed of 7 facilities in Brazil.

Medytox’s Sweeping Victory in Botulinum Toxin Suit against Daewoong- Korean court rules in favor of Medytox, (i) concluding “Daewoong misappropriated Medytox’s toxin strain and manufacturing process when producing its Nabota products,” (ii) ordering Daewoong to pay Medytox damages and to hand over stolen toxin strain to Medytox, and (iii) banning Daewoong from manufacturing and selling Nabota products. Medytox Inc. (CEO HyunHo Jung) won a sweeping victory in the first-instance civil lawsuit it had filed against Daewoong Pharmaceutical Co., Ltd., accusing Daewoong of stealing and misappropriating its trade secrets related to toxin strain and manufacturing process. The 61st Civil Division of Seoul Central District Court (Presiding Judge Oh-seok Kwon) ruled on Feb. 10, 2023 that Daewoong’s Nabota has been developed by stealing Medytox’s botulinum toxin strain and manufacturing process. The Court prohibited Daewoong from manufacturing and selling its toxin products, including Nabota, while ordering Daewoong to hand over its strain to Medytox and discard all toxin products that have already been produced. The Court also ordered Daewoong to pay KRW 40 billion in damages to Medytox. In all, the ruling represented a complete wining by Medytox. With the Court’s decision, Medytox can now reclaim its rights only 5 years and 4 months after it filed the suit against Daewoong in October 2017, when it first raised suspicion that its botulinum toxin strain and manufacturing process had been stolen. The Court found that the strain Daewoong has used in manufacturing its toxin products originated from Medytox’s strain and Daewoong’s argument that it had separated and identified its strain from soil in certain area of Korea was unacceptable, given various evidence submitted to the Court. The Court also found that Daewoong’s manufacturing process was based on the manufacturing process stolen from Medytox, dismissing Daewoong’s claim that its manufacturing process is the result of its independent R&D, on the grounds that Daewoong’s R&D period was too short. The latest Korean Court’s ruling reflected U.S. ITC’s previous decision, under which Daewoong was banned from exporting its toxin products to the U.S. market for 21 months. Long and in-depth deliberation took place at the Korean Court after key evidence and witness statements, expert analysis reports from the ITC proceedings were submitted to the Court. Medytox’s spokesperson said, “this Court ruling is a clear and rightful judgment that is based on indisputable scientific evidence such as DNA sequence test results. We are delighted to witness justice and fairness in Korea. We will strengthen our efforts to protect our rights based on this ruling. We will speed up our legal reviews against additional companies that are suspected of having stolen Medytox’s toxin strain and manufacturing process to commercialize their own toxin products.”